Table 4. Pharmacological treatment by HFpEF diagnosis.
| Pharmacological agent | HFpEF,n = 93, %a | Non-HFpEF,n = 59, %a | P value for comparison |
|---|---|---|---|
| Prescribed medications, mean (SD) | 8.3 (4.0) | 7.8 (3.9) | 0.454 |
| >10 medications | 37 | 30 | 0.398 |
| ACEI | 34 | 37 | 0.698 |
| ARB | 30 | 32 | 0.840 |
| ARNI | 1 | 2 | 0.743 |
| MRA | 12 | 18 | 0.355 |
| Beta-blockers | 48 | 54 | 0.475 |
| Calcium channel blockers | 32 | 40 | 0.315 |
| Loop diuretics | 57 | 51 | 0.456 |
| Any diuretic | 65 | 61 | 0.673 |
| Digoxin | 16 | 22 | 0.334 |
| Statins | 58 | 63 | 0.552 |
| Aspirin | 21 | 28 | 0.316 |
| Other antiplatelet | 7 | 5 | 0.729 |
| Anticoagulation | 51 | 65 | 0.100 |
| Anticoagulation if AFb | 96 | 91 | 0.409 |
| Antidepressants | 16 | 9 | 0.232 |
| Anti-anaemia drugs | 14 | 5 | 0.111 |
| Uric acid-related drugs | 19 | 18 | 0.813 |
| NSAIDs | 2 | 2 | 0.845 |
| Patients with diabetes (n = 44) | |||
| Insulin | 25 | 40 | 0.307 |
| Biguanides | 48 | 47 | 0.927 |
| Sulfonylureas | 15 | 20 | 0.666 |
| SGLT2 inhibitors | 7 | 0 | 0.535 |
| DPP4 inhibitors | 17 | 20 | 0.822 |
| Non-pharmacologic management | |||
| Attended CR in past | 13 | 16 | 0.640 |
| Currently attending CR | 3 | 0 | 0.168 |
aUnless otherwise stated. b n = 48. ACEI = angiotensin-converting enzyme inhibitor. AF = atrial fibrillation. ARB = angiotensin receptor blocker. ARNI = angiotensin receptor-neprilysin inhibitor. CR = cardiac rehabilitation. DPP4 = dipeptidyl peptidase-4. HFpEF = heart failure with preserved ejection fraction. MRA = mineralocorticoid receptor antagonist. NSAIDs = non-steroidal anti-inflammatory drugs. SD = standard deviation. SGLT2 = sodium glucose co-transporter-2.